COVID-19 Antibody Treatment Study Paused
WEDNESDAY, Oct. 14, 2020 -- Enrollment in a study testing an experimental antibody therapy against COVID-19 has been paused by independent monitors.
The study, ACTIV-3, was testing the use of a single antibody with the antiviral drug remdesivir. The antibody is being developed by Eli Lilly and the Canadian company AbCellera, the Associated Press reported. The study has been paused "out of an abundance of caution," Lilly said Tuesday, but the company did not explain what prompted the decision.
The study is sponsored by the U.S. National Institute of Allergy and Infectious Diseases, which did not immediately comment, the AP reported.
After falling ill with COVID-19, President Donald Trump received an experimental two-antibody cocktail from Regeneron Pharmaceuticals Inc. Regeneron and Lilly are both seeking emergency use authorization from the FDA for their COVID-19 treatments while late-stage studies continue, the AP reported.
© 2020 HealthDay. All rights reserved.
Posted: October 2020
Further Support and Information on COVID-19
Read this next
Individuals With Blood Group O Have Lower Risk for COVID-19
WEDNESDAY, Oct. 14, 2020 -- Individuals with blood group O may have a reduced risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and COVID-19...
Immune Responses Long-Lasting After Serious COVID-19
WEDNESDAY, Oct. 14, 2020 -- Protective antibodies persist for months in patients who survive serious COVID-19 infections, according to a study published Oct. 8 in Science...
NIH Launches Trial of Antibody Drugs Against COVID-19
WEDNESDAY, Oct. 14, 2020 -- A study to assess whether certain approved or experimental drugs are effective against COVID-19 and warrant testing in large clinical trials has been...